COVID-19 test kits; nCoV Ag Test (Latex Chromatography Assay) - POCT. Print; Share. ; Twitter; ; Email; Australian sponsor. BGI Health (AU) Company Pty Ltd. ARTG. BGI Health (AU) Company Pty Ltd - Severe acute respiratory syndrome-associated coronavirus IVDs (387550) Manufacturer.

Allplex™ 2019-nCoV Assay is multiplex Real-time PCR assay for simultaneous detection of 3 target genes of SARS-CoV-2 in a single tube. The assay is designed 

The Coronavirus disease (COVID-19) pandemic continues to spread across the world. Hence, there is an urgent need for rapid, simple, 

Request PDF | The Allplex 2019-nCoV (Seegene) assay: which performances are for SARS-CoV-2 infection diagnosis? | Several commercial assays 

The workflow reliably detects 2019-nCoV, and further discriminates 2019-nCoV from SARS-CoV. Through coordination between academic and public laboratories, we confirmed assay exclusivity based on 297 original clinical specimens containing a full spectrum of human respiratory viruses.

SARS-CoV-2 Research Use Only Primer and Probe Sets. IDT offers a wide array of primer and probe sets, as well as plasmid controls, for the identification of SARS-CoV-2 (2019-nCoV). Primers and probes are manufactured in a template-free environment and certified template-free to cycle 45 by NTC testing. Ordering.

The CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel is a molecular in vitro diagnostic test that aids in the detection and diagnosis of SARS-CoV-2 infection and is based on widely used nucleic acid

Allplex™ SARS-CoV-2 Assay é um ensaio de PCR em tempo real multiplex que detecta e identifica em uma única amostra o covid-19 usando quatro genes alvo: RdRP 

The Allplex™ 2019-nCoV Assay is intended for use by qualified, trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time RT-PCR and in vitro

Pipet each assay and sample mix into the IFC inlets. — 2019-nCoV Probe & Primer Kit* Standard BioTools 102-0686 PBS, pH 7.4 Thermo Fisher Scientific™ 10010023

The Allplex 2019-nCoV (Seegene) assay appears as a reliable method, but additional evaluations using more samples are needed. Several commercial assays for SARS-CoV-2 RT-PCR are available but few of them were assessed. We evaluate the Allplex 2019-nCoV (Seegene) assay using 41 nasopharyngeal samples. The rates of agreement were 92.7% and 100% with the GeneFinder COVID-19 plus (Elitech) and the